Pacific Biosciences of California, Inc. (PACB) Stock Price
PACBStock
$1.73−1.70%52W
Market Cap$537.74M
P/E—
PEG Ratio—
Div yield—
Beta2.27
PACB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)0.29%
Price vs S&P 500 (4W)28.53%
VGM Score42.28
PACB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.13 | -$0.14 | -10.41%(-$0.01) | |
| Q1 2026 | -$0.13 | -$0.12 | +8.70%(+$0.01) | |
| Q4 2025 | -$0.13 | -$0.12 | +10.77%(+$0.01) | |
| Q3 2025 | -$0.14 | -$0.12 | +15.11%(+$0.02) | |
| Q2 2025 | -$0.17 | -$0.13 | +21.53%(+$0.04) |
PACB Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.80
3.86
3.86
3.86
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
PACBPacific Biosciences of California, Inc. | D | D | B | 3.4x | 15.2% | 39.2% | -83.5% | $1.73 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Pacific Biosciences of California, Inc.
Pacific Biosciences develops and manufactures DNA sequencing platforms that enable genetic analysis for research and clinical applications. The company's integrated technology helps scientists and clinical researchers identify and resolve complex genetic problems. Revenue is generated primarily from the Americas, with significant contributions from Europe, the Middle East, Africa, and Asia-Pacific.